Biotech: Page 68
-
Permission granted by Biogen
VA leaves Aduhelm off coverage list, recommending against controversial Alzheimer's drug
The decision, which does provide for certain exceptions, is another bump in what's become a rocky market rollout for Biogen's medicine.
By Ned Pagliarulo • Updated Aug. 12, 2021 -
Sarah Silbiger via Getty Images
FDA rejects FibroGen's kidney drug in major blow to company
While the decision was expected after a negative advisory panel last month, it's a significant setback that could trigger cost-cutting at the biotech, which said it will discuss next steps with partner AstraZeneca.
By Kristin Jensen • Aug. 11, 2021 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
NIAID. (2019). "T Regulatory Cells" [Microscope image]. Retrieved from Flickr.
GentiBio raises $157M as cell therapy for immune diseases draw investor interest
The biotech company is working with regulatory T cells, an immune cell type that's become the focus of several newly launched drugmakers like Abata Therapeutics and Sonoma Biotherapeutics.
By Shoshana Dubnow • Aug. 11, 2021 -
Maddie Meyer via Getty Images
Eyeing future outbreaks, Moderna partners with Canadian government on vaccine plant
While Canada has already secured more COVID-19 vaccine doses than it needs, the factory to be built is geared toward combating future pandemics.
By Jonathan Gardner • Aug. 10, 2021 -
Bluebird to wind down business in Europe amid gene therapy struggles
Shares in the biotech sunk in value as the company also announced new safety concerns for one of its leading programs.
By Jacob Bell • Aug. 9, 2021 -
Permission granted by Seagen
SeaGen builds cancer drug pipeline with China biotech deal
The Seattle drugmaker will pay $200 million upfront to acquire a HER2-targeting antibody-drug conjugate from China's RemeGen, giving it a potential challenger to AstraZeneca's Enhertu.
By Ned Pagliarulo • Aug. 9, 2021 -
Startup EQRx to take drug price mission public through $1.8B SPAC deal
A merger with a blank-check company backed by Casdin Capital will greatly expand the resources available to EQRx, which aims to develop competitors to existing drugs and sell them at "radically lower" prices.
By Ned Pagliarulo • Aug. 6, 2021 -
Jacob Bell/BioPharma Dive
Gilead's Kite bets on early-stage biotech to advance allogeneic cell therapies
Appia Bio, which launched with over $50 million in Series A funding earlier this year, will provide preclinical research for two CAR-iNKT candidates, which Kite will pick up should they advance past early clinical testing.
By Shoshana Dubnow • Aug. 5, 2021 -
Regeneron drug extends survival in lung cancer trial, lifting company's hopes in field
The biotech also reported second quarter earnings on Thursday that widely surpassed Wall Street expectations.
By Jonathan Gardner • Aug. 5, 2021 -
Photo illustration by Maura Sadovi/BioPharma Dive; photograph by Carl Court via Getty Images
Moderna says vaccine protective through six months, but warns boosters needed this fall
Final results from the Phase 3 trial that led to the shot's authorization showed efficacy remained high, at 93%, although that data was collected before the delta variant had spread widely.
By Ned Pagliarulo • Aug. 5, 2021 -
How Bayer lured a biotech away from an IPO and into a buyout
Vividion Therapeutics was headed toward an IPO earlier this year, but the company's co-founder said Bayer’s $1.5 billion offer ended up being a more attractive option.
By Shoshana Dubnow • Aug. 5, 2021 -
Permission granted by Biogen
After controversial approval, doctors are still debating how to use Biogen's Alzheimer's drug
Nearly two months since Aduhelm became available, many physicians have yet to use the first treatment approved in the U.S. to slow Alzheimer's disease.
By Jacob Bell • Updated Aug. 3, 2021 -
Sarah Silbiger via Getty Images
FDA rejects a biotech's kidney drug, but some analysts still see a 'sliver of hope'
The agency wants Ardelyx to run another trial to show its drug affects clinical outcomes for patients with chronic kidney disease. Analysts think this could be accomplished, but would take some time.
By Jacob Bell • July 30, 2021 -
A startup raises $117M to deliver gene therapies in a new way
Flagship Pioneering, the biotech incubator that created Moderna, is helping fund Ring Therapeutics, a startup hoping to disrupt gene therapy development through the use of a different viral vector.
By Kristin Jensen • July 28, 2021 -
Amgen pays $900M for Teneobio and bets bigger on next-gen antibody drugs
The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech.
By Ben Fidler • July 28, 2021 -
Elizabeth Regan/BioPharma Dive
An AstraZeneca spinout scores a buyout option from Arena
The potential acquisition marks a fast turnaround for Aristea, one of several biotechs formed from programs AstraZeneca decided not to advance internally.
By Jonathan Gardner • July 27, 2021 -
Justin Sullivan via Getty Images
Regeneron, AstraZeneca team up on targeted drugs for obesity
After screening 650,000 people, Regeneron unearthed a mutation associated with lower weight. AstraZeneca aims to help the biotech make a drug based on its findings.
By Jonathan Gardner • July 27, 2021 -
Sean Gallup via Getty Images
BioNTech, WHO hatch plan to bring mRNA vaccines to Africa
Responding to criticism, the German biotech plans to develop a malaria shot and build manufacturing infrastructure on the continent.
By Jonathan Gardner • July 26, 2021 -
del Aguila III, Ernesto. (2018). "CRISPR Cas9" [Illustration]. Retrieved from Flickr.
Caribou raises $304M in one of gene editing's most lucrative IPOs
The IPO is several times larger than what CRISPR Therapeutics, Intellia and Editas raised several years ago, and ranks well ahead of a more recent offering from gene editing startup Beam.
By Ned Pagliarulo • July 23, 2021 -
Seres, after earlier success, fails a key test for microbiome drugs
A pill made of gut bacteria wasn't effective at treating ulcerative colitis in a closely watched study that was viewed as a proof point for the emerging field.
By Ben Fidler • July 22, 2021 -
Permission granted by Biogen
Biogen executives attack Aduhelm criticism, blaming 'extensive misinformation'
The company responded forcefully to controversy roiling around the Alzheimer's drug's approval, defending its data and interactions with the FDA.
By Jonathan Gardner , Ned Pagliarulo • July 22, 2021 -
Amylyx, faced with longer FDA path for promising ALS drug, gets major cash infusion
A $135 million investment will help the small biotech potentially prepare to launch the treatment in Canada and Europe as well as fund another trial requested by U.S. regulators.
By Ned Pagliarulo • Updated July 20, 2021 -
BioNTech returns to cancer roots with deal for Gilead cell therapy factory
The German biotech purchased Kite Pharma's Gaithersburg, Maryland-based site, along with related research on T cell receptor-based cancer treatments.
By Shoshana Dubnow • July 19, 2021 -
Elizabeth Regan/BioPharma Dive
Cytokinetics heart drug succeeds in mid-stage study, boosting shares
Treatment with one of the biotech's drugs improved heart function in a small trial, an outcome that could help the company rebound and potentially challenge a rival medicine from Bristol Myers Squibb.
By Ned Pagliarulo • July 19, 2021 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
COVID-19 drug developer Adagio plans IPO to cap fast rise
The offering is the latest step in the rapid emergence of Adagio, which raised $465 million and brought a drug to pivotal testing in less than a year.
By Ben Fidler • July 19, 2021
Previous
